* DelSite-enhanced powder vaccines make use of inactivated vaccine antigen and provide both nasal and systemic immunization.
* The composition of DelSite-enhanced vaccines confers adjuvant-like properties, boosting immunostimulation and potentially enabling lower dosing.
DelSite's nasal powder, which is expected to enter human clinical trials for effectiveness against flu early next year, is based on a chemically and functionally distinct high-molecular-weight ionic polysaccharide designed for in situ gelling. The polymer allows dry powder to change into gel particles upon contact with liquids in the nasal cavity. The in-situ gel provides sustained antigen release and prolonged nasal residence, thereby increasing exposure to the antigen that results in increased immune response.
There is a significant unmet global health need for influenza vaccines. All current influenza vaccines are liquid formulations that have a limited shelf life, require refrigeration for storage and distribution and, with the exception of one live vaccine product, are administered by injection.
DelSite's nasal powder influenza vaccine holds distinct advantages over current flu vaccines by providing long-term stability at room temperature, shipping and distribution with no need for refrigeration, and administration without a needle. In addition, the vaccine is preservative-free and induces both mucosal and systemic responses. These attributes make DelSite's nasal powder influenza vaccine particularly well suited for pandemic preparedness when such products may need to be stockpiled for extended periods of time and rapidly distributed and self administered under emergency conditions.
Once DelSite's nasal dry powder technology has been successfully
developed for the influenza vaccine, these same advantages may also prove
useful in formulating other biodefense products and a wide r
|SOURCE Carrington Laboratories, Inc.|
Copyright©2007 PR Newswire.
All rights reserved